Teva Pharmaceutical Industries Target of Unusually High Options Trading (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) was the target of some unusual options trading activity on Wednesday. Investors bought 50,205 call options on the company. This is an increase of 110% compared to the typical daily volume of 23,872 call options.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently bought and sold shares of TEVA. Harel Insurance Investments & Financial Services Ltd. increased its position in Teva Pharmaceutical Industries by 51.4% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock worth $559,622,000 after purchasing an additional 11,334,780 shares in the last quarter. Menora Mivtachim Holdings LTD. increased its position in Teva Pharmaceutical Industries by 31.9% during the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock worth $645,148,000 after purchasing an additional 9,303,978 shares in the last quarter. Phoenix Financial Ltd. increased its position in Teva Pharmaceutical Industries by 31.7% during the 2nd quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock worth $632,882,000 after purchasing an additional 9,094,372 shares in the last quarter. Soundwatch Capital LLC acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $143,533,000. Finally, Maverick Capital Ltd. increased its position in Teva Pharmaceutical Industries by 14,351.6% during the 2nd quarter. Maverick Capital Ltd. now owns 4,377,690 shares of the company’s stock worth $73,370,000 after purchasing an additional 4,347,398 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on TEVA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Friday, October 3rd. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries has an average rating of “Buy” and an average price target of $25.57.

Teva Pharmaceutical Industries Trading Up 21.4%

Shares of TEVA stock traded up $4.38 during trading hours on Wednesday, hitting $24.84. 27,099,222 shares of the company were exchanged, compared to its average volume of 11,639,556. The firm has a market cap of $28.48 billion, a PE ratio of -155.10, a PEG ratio of 1.11 and a beta of 0.71. Teva Pharmaceutical Industries has a 1 year low of $12.47 and a 1 year high of $24.51. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The firm has a fifty day moving average of $19.37 and a 200 day moving average of $17.66.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.